|Mr. John E. Bailey Jr.||CEO, Pres & Director||1.04M||N/A||1965|
|Ms. Jennifer K. Moses CPA||Chief Financial Officer||606.27k||58.05k||1975|
|Dr. Mark A. Velleca M.D., Ph.D.||Sr. Advisor & Director||242.69k||N/A||1964|
|Dr. Rajesh K. Malik Ch.B., M.B., M.D.||Chief Medical Officer and Sr. VP of R&D||596.37k||1.48M||1959|
|Mr. Mark Avagliano||Chief Bus. Officer||606.05k||N/A||1976|
|Mr. Andrew Perry||Chief Commercial Officer||568.6k||N/A||1973|
|Mr. Terry L. Murdock||Chief Operating Officer||N/A||N/A||1960|
|Mr. Alexander D. Smith M.S.||VP of Technical Operations||N/A||N/A||N/A|
|Dr. Jay C. Strum Ph.D.||Chief Scientific Officer||N/A||N/A||1964|
|Mr. William C. Roberts||VP of Investor Relations & Corp. Communications||N/A||N/A||1969|
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.
G1 Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2022 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 9.